PT  - JOURNAL ARTICLE
AU  - LEE S. SIMON
AU  - C. VIBEKE STRAND
AU  - MAARTEN BOERS
AU  - PETER M. BROOKS
AU  - DAVID HENRY
AU  - PETER S. TUGWELL
TI  - Observations from the OMERACT Drug Safety Summit, May 2008
AID  - 10.3899/jrheum.090590
DP  - 2009 Sep 01
TA  - The Journal of Rheumatology
PG  - 2110--2113
VI  - 36
IP  - 9
4099  - http://www.jrheum.org/content/36/9/2110.short
4100  - http://www.jrheum.org/content/36/9/2110.full
SO  - J Rheumatol2009 Sep 01; 36
AB  - Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions.